ClinicalTrials.gg
RecruitingNCT06393803Updated May 7, 2024

Phase 1 Study of KH607 Tablets

A Phase 1 interventional study of 2mg KH607 tablets and 5mg KH607 tablets in Healthy, sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-07.

Sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study was a single-center, randomized, double-blind, placebo-controlled study divided into a Single Ascending Dose (SAD) stage and a Multiple Ascending Dose (MAD) stage. The primary objective was to evaluate the safety and tolerability of KH607 tablets in Chinese healthy volunteers.

Read the detailed description

This study consists of two parts: Part 1-SAD phase and Part 2- MAD phase. There will be eight cohorts in Part 1 and three cohorts in Part 2 of this study.

The SAD study will enroll approximately 58 HVs across 8 dose cohorts. The dose cohorts will include the following dose levels: 2 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50mg and 60 mg. All participants in Part 1 will be administered with a single oral dose of KH607 or its matching placebo under fasted condition.

Approximately 30 HVs will be enrolled in the multiple ascending dose study. The dose cohorts will include the following dose levels: 10 mg, 20 mg, 30 mg.At each cohort, 10 subjects will be randomized in a ratio of 8:2 to be receive KH607 or placebo once daily for continuous 7 days (QDx7d) in a double-blind manner.

Additionally, this study will explore the effect of food on the PK of a single oral administration of KH607 in one selected SAD cohort.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Chengdu Kanghong Pharmaceutical Group Co., Ltd. is the lead sponsor of 11 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult, male and female volunteers, 18 to 55 years of age, inclusive.
  2. Male weight ≥ 50kg, female weight ≥ 45kg, and ≥ 19 to ≤ 28 kg/m2 at the screening period.

Exclusion criteria

Exclusion Criteria:

  1. Vulnerable groups include the Investigator and his or her immediate family members (spouse, parents, children, siblings), non-immediate family members involved in the study, or individuals who may be participating under coercion or undue influence.
  2. Subjects whose C-SSRS suggests that they are at risk for suicide at the screening period, or with the risk for suicide based on the Investigator's clinical judgment, or with a history of suicidal or self-harming behavior.
  3. Subjects with SSS ≥3 or MOAA/S ≤4 during the screening period.
  4. Subjects with a history of surgery for gastrointestinal disorders or current GI disorders that may interfere with drug absorption, or who have undergone major surgery within the 3 months prior to the screening period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    KH607 Cohort 1

    Subject received a single KH607 tablets dose of 2mg KH607 tablets or matching placebo.

    Drug: 2mg KH607 tablets

  • Experimental
    KH607 Cohort 2

    Subject received a single KH607 tablets dose of 5mg KH607 tablets or matching placebo.

    Drug: 5mg KH607 tablets

  • Experimental
    KH607 Cohort 3

    Subject received a single KH607 tablets dose of 10mg KH607 tablets or matching placebo.

    Drug: 10mg KH607 tablets

  • Experimental
    KH607 Cohort 4

    Subject received a single KH607 tablets dose of 20mg KH607 tablets or matching placebo.

    Drug: 20mg KH607 tablets

  • Experimental
    KH607 Cohort 5

    Subject received a single KH607 tablets dose of 30mg KH607 tablets or matching placebo.

    Drug: 30mg KH607 tablets

  • Experimental
    KH607 Cohort 6

    Subject received a single KH607 tablets dose of 40mg KH607 tablets or matching placebo.

    Drug: 40mg KH607 tablets

  • Experimental
    KH607 Cohort 7

    Subject received a single KH607 tablets dose of 50mg KH607 tablets or matching placebo.

    Drug: 50mg KH607 tablets

  • Experimental
    KH607 Cohort 8

    Subject received a single KH607 tablets dose of 60mg KH607 tablets or matching placebo.

    Drug: 60mg KH607 tablets

  • Experimental
    KH607 Cohort 9

    Subject received 10mg KH607 or matching placebo, oncely daily from Day 1 to Day 7.

    Drug: 10mg KH607 tablets

  • Experimental
    KH607 Cohort 10

    Subjects receive 20mg KH607 or matching placebo, once daily from Day 1 to Day 7.

    Drug: 20mg KH607 tablets

  • Experimental
    KH607 Cohort 11

    Subjects receive 30mg KH607 or matching placebo, once daily from Day 1 to Day 7.

    Drug: 30mg KH607 tablets

Interventions

  • Drug2mg KH607 tablets

    Subject receive KH607 tablets or placebo orally single dose.

  • Drug5mg KH607 tablets

    Subject receive KH607 tablets or placebo orally single dose.

  • Drug10mg KH607 tablets

    Subject receive KH607 tablets or placebo orally single dose or multiple doses.

  • Drug20mg KH607 tablets

    Subject receive KH607 tablets or placebo orally single dose or multiple doses.

  • Drug30mg KH607 tablets

    Subject receive KH607 tablets or placebo orally single dose or multiple doses.

  • Drug40mg KH607 tablets

    Subject receive KH607 tablets or placebo orally single dose.

  • Drug50mg KH607 tablets

    Subject receive KH607 tablets or placebo orally single dose.

  • Drug60mg KH607 tablets

    Subject receive KH607 tablets or placebo orally single dose.

06

What researchers measure

Primary outcomes

  1. 12-lead ECGs

    Using a standard 12-lead ECG machine that automatically calculates heart rate and measures PR interval, RR interval, QRS interval, QT interval and QTc interval. ECGs will be reviewed by the Investigator on an ongoing basis as safety assessments.

    Time frame: Screening up to Part 1 Days, Part 2 Day14.

  2. Physical Examination

    Time frame: Screening up to Part 1 Days, Part 2 Day14.

  3. 12-lead ECGs

    Using a standard 12-lead ECG machine that automatically calculate heart rate and measures PR interval, RR interval, QRS interval, QT interval, QTc interval. ECGs will be reviewed by the Investigator on an ongoing basis as safety assessments.

    Time frame: Screening up to Part 2 Day14.

  4. Stanford Sleepiness Scale

    Participants rate their current sleepiness on a scale of 1 to 7, where scale of 1 indicates feeling active, vital, alert, or wide awake. Scale of 7 indicates no longer fighting sleep, sleep onset soon, and having dream-like thoughts.

    Time frame: Screening up to Part 1 Day3,Part 2 Day14.

  5. Modified Observer's Assessment of Alertness/Sedation scale

    The MOAA/S ranges from 0 to 5, with a score of 5 defined as awake or minimally sedated, and a score of 0 defined as general anaesthesia.

    Time frame: Screening up to Part 1 Day3,Part 2 Day14.

Secondary outcomes

  1. Columbia-Suicide Severity Rating Scale

    The C-SSRS scale consists of three subscales: suicidal ideation, intensity of ideation and suicidal behavior.

    Time frame: Screening up to Part 1 Day3,Part 2 Day14.

  2. Observed maximum plasma concentration (Cmax)

    Time frame: Up to 48 hours after dosing in Part 1.

  3. Time to reach maximum plasma concentration (Tmax)

    Time frame: Up to 48 hours after dosing in Part 1.

  4. Elimination Halflife (T1/2)

    Time frame: Up to 48 hours after dosing in Part 1.

  5. Area under the concentration-time curve from time zero to last time of quantifiable concentration(AUC0-t)

    Time frame: Up to 48 hours after dosing in Part 1.

  6. Apparent Distribution Volume (Vd)

    Time frame: Up to 48 hours after dosing in Part 1.

  7. Apparent Total Plasma Clearance (CL)

    Time frame: Up to 48 hours after dosing in Part 1.

  8. Elimination Rate Constant (Kel)

    Time frame: Up to 48 hours after dosing in Part 1.

  9. Mean Residence Time(MRT)

    Time frame: Up to 48 hours after dosing in Part 1.

  10. Steady-state valley concentration(Css,min)

    Time frame: Up to 24 hours after Day7 dosing in Part 2.

  11. Steady-state peak concentration(Css,max)

    Time frame: Up to 24 hours after Day7 dosing in Part 2.

  12. Mean steady-state blood concentration(Css,av)

    Time frame: Up to 24 hours after Day7 dosing in Part 2.

  13. Steady state area under the curve(AUC0-tau)

    Time frame: Up to 24 hours after Day7 dosing in Part 2.

  14. Accumulation Index(Rac)

    Time frame: Up to 24 hours after Day7 dosing in Part 2.

07

Study locations

1 of 1 sites recruiting
  • Beijing Anding Hospital Affiliated to Capital Medical University
    Beijing, China
    Recruiting
    • Gang Wang, Medical Doctor · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Oct 2024, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
May 1, 2024
StartActual
Oct 21, 2023
Primary completionEst.
Oct 30, 2024
CompletionEst.
Oct 30, 2024
Last update
May 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06393803
Responsible party
Sponsor
First posted
May 1, 2024
Start date
Oct 21, 2023
Primary completion
Oct 30, 2024 (estimated)
Completion
Oct 30, 2024 (estimated)
Last update
May 7, 2024

Study contacts

Ling Song
Contact
022516@cnkh.com
028-81258178

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion